Mangorx introduces oral tirzepatide glp-1 receptor agonist for advanced weight loss solutions

Dallas, texas, oct. 03, 2024 (globe newswire) -- mangoceuticals, inc. (nasdaq: mgrx) (“mangorx” or the “company”), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, announces the release of its latest innovation, “trim,” a compounded, oral dissolvable tirzepatide tablet. available for purchase at $399 per month, this new product offers patients an advanced and convenient alternative to injectable therapies.
MGRX Ratings Summary
MGRX Quant Ranking